ATE102250T1 - Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion. - Google Patents

Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.

Info

Publication number
ATE102250T1
ATE102250T1 AT85105405T AT85105405T ATE102250T1 AT E102250 T1 ATE102250 T1 AT E102250T1 AT 85105405 T AT85105405 T AT 85105405T AT 85105405 T AT85105405 T AT 85105405T AT E102250 T1 ATE102250 T1 AT E102250T1
Authority
AT
Austria
Prior art keywords
yeast
promoter region
pcl
deposited
sub
Prior art date
Application number
AT85105405T
Other languages
English (en)
Inventor
Steven Rosenberg
Patricia Tekamp-Olson
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE102250T1 publication Critical patent/ATE102250T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • C07K14/8125Alpha-1-antitrypsin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0089Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT85105405T 1984-05-11 1985-05-03 Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion. ATE102250T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60954084A 1984-05-11 1984-05-11
EP85105405A EP0164556B1 (de) 1984-05-11 1985-05-03 Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion

Publications (1)

Publication Number Publication Date
ATE102250T1 true ATE102250T1 (de) 1994-03-15

Family

ID=24441222

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85105405T ATE102250T1 (de) 1984-05-11 1985-05-03 Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.

Country Status (4)

Country Link
EP (2) EP0164556B1 (de)
AT (1) ATE102250T1 (de)
CA (1) CA1281671C (de)
DE (1) DE3587759T2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523215A (en) * 1985-03-28 1996-06-04 Chiron Corporation Enhanced purification and expression of insoluble recombinant proteins
US5342921A (en) * 1985-03-28 1994-08-30 Chiron Corporation Superoxide dismutase fusion polypeptides for expression of mammalian proteins
EP0225887B1 (de) * 1985-04-08 1994-06-08 Amgen Inc. Verfahren und hybridpromotor zur steuerung der exogenen gentranskription
GB8521496D0 (en) * 1985-08-29 1985-10-02 Ciba Geigy Ag Repressible yeast promoters
ES2028779T3 (es) * 1985-10-03 1992-07-16 Green Cross Corporation Promotor de levadura y procedimiento para preparar proteina heterologa.
EP0237913A1 (de) * 1986-03-21 1987-09-23 Miles Inc. Transkriptions-Effektor-Sequenzen
JPS62236496A (ja) * 1986-04-07 1987-10-16 Green Cross Corp:The HBsAgの製造方法
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein
GB8620926D0 (en) * 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
ATE121776T1 (de) * 1986-09-19 1995-05-15 Zymogenetics Inc Expression des biologisch aktiven faktors xiii.
US5013652A (en) * 1986-10-14 1991-05-07 Genex Corporation Composite yeast vectors
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
NO177065C (no) * 1988-09-26 1995-07-12 Labofina Sa Framgangsmåte for framstilling av enzymatisk aktivt humant lysozym
JPH03155791A (ja) * 1989-11-14 1991-07-03 Green Cross Corp:The 雑種プロモーター
FR2656531B1 (fr) * 1989-12-29 1992-04-24 Sanofi Sa Promoteur artificiel pour l'expression de proteines dans le levure.
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
JPH04108389A (ja) * 1990-08-30 1992-04-09 Tonen Corp 酵母において機能する大腸菌由来上流制御配列
IE914102A1 (en) 1990-11-26 1992-06-03 Genetics Inst Expression of pace in host cells and methods of use thereof
US5407822A (en) * 1991-10-02 1995-04-18 Sanofi Artificial promoter for the expression of proteins in yeast
LT3988B (en) 1992-02-17 1996-06-25 Fermentas Biotech Inst Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof
RU2115730C1 (ru) * 1992-03-03 1998-07-20 Акционерное общество "Биофа" Рекомбинантная плазмида pfs 19, определяющая синтез поверхностного антигена s вируса гепатита b человека
JPH08510240A (ja) 1993-05-12 1996-10-29 カイロン コーポレイション C型肝炎ウイルスe2/ns1領域の保存モチーフ
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
JP2000507087A (ja) 1995-12-22 2000-06-13 ギスト ブロカデス ベスローテン ファンノートシャップ ファフィア株を形質転換する改良法、そのようにして得られた形質転換したファフィア株及び前記方法における組換えdna
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
ATE446368T1 (de) 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
US6087128A (en) * 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261345A3 (de) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
RU2245366C2 (ru) 1999-04-30 2005-01-27 Чирон С.Р.Л. Антиген neisseria, кодирующая его нуклеиновая кислота, их использование
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6297013B1 (en) * 1999-06-24 2001-10-02 Dnab Diagnostics Inc. Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT2275552E (pt) 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
US6709863B2 (en) 1999-12-08 2004-03-23 Iowa State University Research Foundation Nucleic acid molecules encoding multiple start codons and histidine tags
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
RU2200196C2 (ru) * 2000-11-22 2003-03-10 Государственный научно-исследовательский институт особо чистых биопрепаратов РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPHO-SOD23, КОДИРУЮЩАЯ СИНТЕЗ СУПЕРОКСИДДИСМУТАЗЫ ЧЕЛОВЕКА, И ШТАММ Saccharomyces cerevisiae № Д-11 ВНИИСХМ-ПРОДУЦЕНТ СУПЕРОКСИДДИСМУТАЗЫ ЧЕЛОВЕКА
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
AU2003243316A1 (en) 2002-05-24 2003-12-12 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ME01366B (me) 2003-11-21 2013-12-20 Nps Allelix Corp POSTUPAK ZA PROIZVODNJU PEPTIDA 2 NALIK NA GLUKAGON l NJIHOVIH ANALOGA
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
US8946510B2 (en) 2004-04-09 2015-02-03 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
MX2007000728A (es) 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
CA2927595C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US20080317670A1 (en) 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
HRP20120522T1 (hr) 2007-03-30 2012-08-31 Ambrx Modificirani fgf-21 polipeptidi i njihova uporaba
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
MX2011003196A (es) 2008-09-26 2011-04-27 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
DK2342223T3 (en) 2008-09-26 2017-07-24 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PH12013500241A1 (en) 2010-08-17 2013-03-11 Ambrx Inc Modified relaxin polypeptides and their uses
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR76274B (de) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
GB8314961D0 (en) * 1983-05-31 1983-07-06 Kingsman A J Dna sequence
DE3485284D1 (de) * 1983-10-03 1992-01-02 Chiron Corp Klonieren von superoxid-dismutase und expression in mikroorganismen.
DE3585969D1 (de) * 1984-06-14 1992-06-11 Chiron Corp Protease-inhibitoren des alpha-1-antitrypsin typs mit modifizierter aktiever stelle und deren herstellung.
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
EP0196056B1 (de) * 1985-03-28 1991-05-22 Chiron Corporation Expression durch Verwendung von Fusionsgenen für Proteinproduktion

Also Published As

Publication number Publication date
EP0480480A3 (en) 1992-06-10
CA1281671C (en) 1991-03-19
DE3587759D1 (de) 1994-04-07
EP0480480A2 (de) 1992-04-15
DE3587759T2 (de) 1994-07-07
EP0164556B1 (de) 1994-03-02
EP0164556A3 (en) 1987-01-14
EP0164556A2 (de) 1985-12-18

Similar Documents

Publication Publication Date Title
DE3587759D1 (de) Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
WO1998027114A3 (en) Mammalian cell surface antigens; related reagents
EP0260148A3 (de) Rekombinantes Expressionsverfahren, Vektor und tranformierte Zellen
EP0185444A3 (en) Cloning and expression of htlv-iii dna
KR880014110A (ko) 인체 프로아포지방단백질 a-i의 발현
WO2002006457A3 (en) Novel lipase genes
EP1114864A3 (de) Oberflächenantigene aus Säugern mit Strukturmotifen die charakteristisch für Mitglieder der TNF Liganden Familie sind
IE831211L (en) Cloning vectors for expression of exogenous protein
KR840005745A (ko) B형 간염비루스 유전자를 삽입한 조환 플라스미드, 이 조환 플라스미드로 전환된 효모 및 b형 간염비루스 표면항원의 제조방법
AU3025597A (en) Method of providing novel dna sequences
EP0248637A3 (de) Induktion von Galaktose regulierter Genexpression in Hefe
KR960705929A (ko) 신규한 Fas 단백질 및 그것의 사용방법(NOVEL FAS PROTEIN AND METHODS OF USE THEREOF)
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
EP0228036A3 (de) Verfahren zur Herstellung von spezifischen Polypeptiden in virusinfizierten Insektzellen und daraus isolierte Polypeptide
AU5961596A (en) Method for expression and isolation of biologically active m olecules in urine
DE3773512D1 (de) Vektor und verfahren zur erreichung einer hohen expression in zellen.
FI970428A0 (fi) Soluja, joissa on CD4-houkutusreseptoreita ja vastaavia molekyylejä ja menetelmiä
WO2000015772A3 (en) Recombinant protein production in urine
ES2075068T3 (es) Procedimiento de preparacion de una proteina mediante levaduras que utiliza un sistema inducible, vectores y cepas transformadas correspondientes.
KR880701285A (ko) Aids 비루스의 f단백질을 함유하는 백신
MX9603266A (es) Genes de timocina de mamiferos.
KR890004727A (ko) Hiv-2 비루스 단백질의 발현을 위한 벡터, aids의 원인체중 하나, 이 비루스에 의해 감염되거나 형질 전환된 세포 배양물, 얻어진 단백질, 얻어진 백신 및 항체
ES2136285T3 (es) Adn que codifica el precursor de la proteinasa ii de cisteina relacionada con la enzima convertidora de interleucina 1-beta (icerel-ii).
EP0346702A3 (de) Transfizierte Zellinien, die isolierte Gene der karzinoembryonale Antigenfamilie exprimieren
KR880004092A (ko) 두창비루스의 a-형 봉입체용 유전자

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time